Tags

Type your tag names separated by a space and hit enter

Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
BioDrugs. 2009; 23(4):253-67.B

Abstract

Boostrix is a three-pertussis component, combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine administered as a single intramuscular dose in adolescents or adults aged 10-64 years. Large, well designed trials conducted in the US in adolescents aged 10-18 years and in adults aged 19-64 years showed that serum concentrations of anti-pertussis antibodies approximately 1 month after Boostrix administration were noninferior to those previously shown to have a protective effect in infants following a primary regimen of combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine. Protective serum concentrations of anti-diphtheria and anti-tetanus antibodies were achieved in essentially all (>or=99.9%) adolescents randomized to receive Boostrix or tetanus and diphtheria toxoids (Td) vaccine, and Boostrix was noninferior to Td vaccine for these endpoints. Similarly high seroprotection rates against diphtheria and tetanus were demonstrated with Boostrix and a five-pertussis component Tdap booster vaccine (Adacel) in a large, randomized study in adults; Boostrix was noninferior to Adacel for these outcomes. Reactogenicity data indicate that the vaccine is generally well tolerated in terms of solicited local and general symptoms in both adults and adolescents. Moreover, the importance of single-dose booster vaccination with a Tdap vaccine (such as Boostrix) in these populations is highlighted in current immunization guidelines. Therefore, as a single-dose booster vaccine, Boostrix provides a useful option to reduce pertussis morbidity and maintain the standard of care for tetanus and diphtheria protection in individuals aged 10-64 years.

Authors+Show Affiliations

Wolters Kluwer Health | Adis, Mairangi Bay, North Shore, Auckland, New Zealand. demail@adis.co.nz

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19697967

Citation

Plosker, Greg L.. "Combined, Reduced-antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix): a Review of Its Use as a Single-dose Booster Immunization in Individuals Aged 10-64 Years in the US." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 23, no. 4, 2009, pp. 253-67.
Plosker GL. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US. BioDrugs. 2009;23(4):253-67.
Plosker, G. L. (2009). Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 23(4), 253-67. https://doi.org/10.2165/11202770-000000000-00000
Plosker GL. Combined, Reduced-antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix): a Review of Its Use as a Single-dose Booster Immunization in Individuals Aged 10-64 Years in the US. BioDrugs. 2009;23(4):253-67. PubMed PMID: 19697967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US. A1 - Plosker,Greg L, PY - 2009/8/25/entrez PY - 2009/8/25/pubmed PY - 2010/4/20/medline SP - 253 EP - 67 JF - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy JO - BioDrugs VL - 23 IS - 4 N2 - Boostrix is a three-pertussis component, combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine administered as a single intramuscular dose in adolescents or adults aged 10-64 years. Large, well designed trials conducted in the US in adolescents aged 10-18 years and in adults aged 19-64 years showed that serum concentrations of anti-pertussis antibodies approximately 1 month after Boostrix administration were noninferior to those previously shown to have a protective effect in infants following a primary regimen of combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine. Protective serum concentrations of anti-diphtheria and anti-tetanus antibodies were achieved in essentially all (>or=99.9%) adolescents randomized to receive Boostrix or tetanus and diphtheria toxoids (Td) vaccine, and Boostrix was noninferior to Td vaccine for these endpoints. Similarly high seroprotection rates against diphtheria and tetanus were demonstrated with Boostrix and a five-pertussis component Tdap booster vaccine (Adacel) in a large, randomized study in adults; Boostrix was noninferior to Adacel for these outcomes. Reactogenicity data indicate that the vaccine is generally well tolerated in terms of solicited local and general symptoms in both adults and adolescents. Moreover, the importance of single-dose booster vaccination with a Tdap vaccine (such as Boostrix) in these populations is highlighted in current immunization guidelines. Therefore, as a single-dose booster vaccine, Boostrix provides a useful option to reduce pertussis morbidity and maintain the standard of care for tetanus and diphtheria protection in individuals aged 10-64 years. SN - 1179-190X UR - https://www.unboundmedicine.com/medline/citation/19697967/Combined_reduced_antigen_content_tetanus_diphtheria_and_acellular_pertussis_vaccine__Boostrix_:_a_review_of_its_use_as_a_single_dose_booster_immunization_in_individuals_aged_10_64_years_in_the_US_ L2 - https://dx.doi.org/10.2165/11202770-000000000-00000 DB - PRIME DP - Unbound Medicine ER -